cyclic adenosine monophosphate

Cyclic AMP (cAMP)(Adenosine 3',5'-cyclophosphate) 是有丝分裂信使，可以促进 G1期到 S 期的细胞周期进程。

Gizzerosine 2HCl是鱼粉热处理过程中产生的一种物质，可诱导的肉鸡雏鸡组织病理学病变，可提高离体鸡原产鸡的细胞内环腺苷-3'，5'-单磷酸水平。

Roflumilast (APTA 2217) 是一种口服的长效 4 型磷酸二酯酶抑制剂 (PDE4)，具有抗炎和潜在的抗肿瘤活性，作用于PDE4A1，PDEA4，PDEB1和PDEB2，IC50分别为 0.7，0.9，0.7 和 0.2 nM。

Salbutamol (Albuterol) 是短效的 β2 肾上腺素受体激动剂，用于哮喘和慢性阻塞性肺疾病(COPD) 引发的支气管痉挛的研究。

Ritodrine hydrochloride (NSC 291565) 是一种 β-2肾上腺素受体激动剂。

(+)-pinoresinol-β-D-glucoside; (+)-pinor 是连翘中主要的活性呋喃类木脂素。它显示出抗氧化、降血压和环磷酸腺苷 (cAMP) 磷酸二酯酶抑制活性。

Lixazinone 是一种环状腺苷酸磷酸二酯酶 (cAMP PDE) 抑制剂及心脏强化剂。

Lixazinone sulfate anhydrous 是一种环磷酸腺苷磷酸二酯酶 (cAMP PDE) 抑制剂及心脏强化剂。

Lixazinone sulfate 是一种环磷酸腺苷磷酸二酯酶（cAMP PDE）抑制剂，同时具有强心作用。

Trequinsin HCl是一种依赖于环磷酸腺苷(cAMP)的磷酸二酯酶(PDE) 3抑制剂。它促进cAMP的积累并增加细胞膜电容。

GLP-1R agonist 27 (compound 21) 是一种高效且具有口服活性的GLP-1R激动剂，能够促进环磷酸腺苷 (cAMP) 的积累，降低血糖水平和食物摄入量，具有研究肥胖和2型糖尿病 (T2DM) 的潜力。

PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor that acts by targeting the cyclic adenosine monophosphate (cAMP) cAMP-response element-binding protein (CREB) pathway.

Griseolic acid is a cyclic adenosine 3',5'-monophosphate phosphodiesterase II inhibitor.

BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). In addi

L-750,667 Trihydrochloride是一种选择性的 D4 多巴胺受体(D4 dopamine receptor)拮抗剂，具有高效的优点（Ki＝0.51 nM）。通过逆转多巴胺诱导的对cAMP（环磷酸腺苷，cyclic adenosine monophosphate）积累的抑制，L-750,667 Trihydrochloride 可对中枢神经系统中 D4 受体的进行研究。

Tocladesine, a cyclic adenosine monophosphate (cAMP) receptor agonist, is used potentially for the treatment of colorectal cancer.

CK 2289 is an inhibitor of type III cyclic 3'5' -adenosine monophosphate phosphodiesterase with potential use in the treatment of congestive heart failure.

Indimilast is used to inhibit phosphodiesterase IV that regulates lung inflammation and causes bronchiectasis by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells. Potential to treat chronic obst

ethyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 又称 EAPT，是一种有效的选择性 PDE4抑制剂，调节细胞内环腺苷酸(cAMP)水平。它已被用于多种科研应用，包括 cAMP 介导的信号转导通路的研究，并有潜力作为治疗炎症和免疫相关疾病的药物。

PDE1-IN-4 是有效的、选择性的 PDE1 (磷酸二酯酶 -1) 抑制剂，能够作用于 PDE1C (IC50: 10 nM)、PDE1A (IC50: 145 nM) 和 PDE1B (IC50: 354 nM)。PDE1-IN-4 能够调控 cAMP (3′,5′- 环磷酸腺苷) 和 cGMP (3′,5′- 环磷酸鸟苷)，表现出抗纤维化效果。PDE1-IN-4 能够抑制 TGF-β1 诱导的人肺成纤维细胞分化。PDE1-IN-4 能够用于研究特发性肺纤维化 (IPF)。

Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobic bacteria. Cefminox shows excellent in vivo efficacy (ED50) which is higher than would be expected from its in vitro activity (MIC). Moreover, cefminox possesses more potent activity in suppression of bacterial regrowth than other cephems[1]. Cefminox (Sodium) was the most active beta-lactam, with an MIC at which 50% of isolates are inhibited (MIC50) of 1.0 microg ml and an MIC90 of 16.0 microg ml. Cefminox was especially active against Bacteroides fragilis (MIC90, 2.0 microg ml), Bacteroides thetaiotaomicron (MIC90, 4.0 microg ml), fusobacteria (MIC90, 1.0 microg ml), peptostreptococci (MIC90, 2.0 microg ml), and clostridia, including Clostridium difficile (MIC90, 2.0 microg ml)[2]. The use of a single preoperative dose of cefminox was similar in efficacy to 3 doses of cefoxitin administered every 4 hours, and that the serum and tissue concentrations attained provide adequate antibiotic coverage[3]. Moreover, cefminox as a dual agonist of IP (Prostacyclin receptor) and PPARγ (peroxisome proliferator-activated receptor-gamma) that significantly inhibits PASMC proliferation by up-regulation of PTEN (phosphatase and tensin homolog) and cAMP ( cyclic adenosine monophosphate), suggesting that it has potential for treatment of PAH(pulmonary arterial hypertension)[4].

PhosphodiesteraseII，即磷酸二酯酶 2，主要参与水解重要的第二信使环磷酸腺苷 (cAMP) 和环磷酸鸟苷 (cGMP)，常用于生化研究。PhosphodiesteraseII 表达于多种组织，如肾上腺髓质、脑、心脏、血小板、巨噬细胞和内皮细胞，可参与调节许多不同的细胞内过程。

C82 acts as an inhibitor of Mycobacterium tuberculosis (Mtb) cyclic dinucleotide phosphodiesterase (CdnP), with an IC50 value of 17.5 µM. This particular enzyme is responsible for breaking down cyclic di-AMP (c-di-AMP) into adenosine 5'-monophosphate (AMP). Notably, C82 demonstrates selectivity for Mtb CdnP over other bacterial cyclic dinucleotide phosphodiesterases (CDN PDEs) such as Yybt, RocR, and Group B Streptococcus (GBS) CdnP, as well as the mammalian CDN PDE ENPP1, and the viral CDN PDE poxin, showing effectiveness at a concentration of 200 µM.

Denbufylline (BRL 30892) 是一种磷酸二酯酶-4 (PDE4) 抑制剂，通过抑制细胞内 cAMP (环磷酸腺苷) 的降解来升高细胞内 cAMP 水平，从而调节多种细胞功能。Denbufylline 可用于慢性阻塞性肺病 (COPD)、哮喘及其他炎症性疾病的研究。